Physician profile

Ellen G Miller

Pulmonary Disease · Lincoln, NE

NPI 1932178555

$1,244.32

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $234.61 2019
Glaxosmithkline, LLC. $199.20 2019
Jazz Pharmaceuticals INC. $108.59 2019-2022
Grifols USA, LLC $86.90 2019-2022
Regeneron Healthcare Solutions, INC. $74.23 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $55.56 2020-2022
Genzyme Corporation $54.26 2019-2020
Harmony Biosciences LLC $53.46 2022
Amgen INC. $53.27 2022
Mylan Specialty L.P. $46.37 2019
Philips North America LLC $41.62 2019-2020
Electromed, INC. $32.26 2022
Janssen Pharmaceuticals, INC $30.96 2019-2020
Allergan, INC. $29.12 2020
Novartis Pharmaceuticals Corporation $26.64 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Circassia INC. $23.55 2019-2020
Insmed, INC. $16.24 2021
Pfizer INC. $13.96 2022
Axsome Therapeutics, INC. $13.78 2022
Merck Sharp & Dohme LLC $13.18 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $12.60 2022
Genentech USA, INC. $12.32 2019
Shire North American Group INC $11.64 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ellen G Miller

$1,244.32

in general payments reported 2019-2025

Years
2019-2022
Top company
Sunovion Pharmaceuticals INC.

https://glasscript.com/doctor/313884/ellen-g-miller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.